Key facts
- Centivax’s last known valuation is $95.0M (Jul 2025).
- It has raised $92.0M; the latest was Later Stage VC ($37.0M) in Mar 2026.
- Notable investors include NFX, Amplify Partners, Future Ventures (San Francisco), Patrick Collison, BOLD Capital Partners — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Centivax
- ·The full record, as it builds
Funding rounds
No funding rounds for Centivax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Centivax
Developer of a broad-spectrum vaccine designed to treat and eradicate rapidly mutating pathogens. The company utilizes computational immune engineering to develop therapeutic monoclonal antibodies against a variety of targets and builds a panel of neutralizing antibodies against severe acute respiratory syndrome coronavirus, enabling public health agencies, research institutions, and global healthcare systems to reduce outbreak risk and improve long term pandemic preparedness.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2019
- Employees
- 32
- Website
- centivax.com/
- Ownership
- Privately Held (backing)
Centivax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Centivax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Centivax in its N-PORT filings yet. We sweep new filings monthly.